KALA BIO, Inc. Common Stock
$0.52
$0.01 (+2.74%)
$0.51Day Range$0.54
Key Statistics
Market Cap
$10.09M
Shares Outstanding
19.3M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jul 20, 2017
Round Lot
100
Locale
US
Trading Data
Day Open
$0.54
Day High
$0.54
Day Low
$0.51
Volume
174.4K
VWAP
$0.53
Prev Close
$0.51
Transactions
--
Acc. Volume
--
About KALA BIO, Inc. Common Stock
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
PHARMACEUTICAL PREPARATIONSSIC 28346 employees1167 MASSACHUSETTS AVENUE, ARLINGTON, MA, 02476781-996-5252IPO Jul 20, 2017US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001479419
- Composite FIGI
- BBG001J2MVT8
- Share Class FIGI
- BBG001V0GBM6
- Ticker Root
- KALA
- SIC Code
- 2834
About KALA BIO, Inc. Common Stock (KALA) Stock
KALA BIO, Inc. Common Stock (KALA) closed the 2026-09-16 session at $0.52, up 2.74% versus the previous close (+0.01). The stock opened at $0.54 and traded between $0.51 and $0.54 during that session. Session trading volume was 174K shares. The volume-weighted average price (VWAP) is $0.53.
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
KALA BIO, Inc. Common Stock has a market capitalization of $10.1 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. KALA is listed on the XNAS exchange. The company employs approximately 6 people. KALA BIO, Inc. Common Stock is headquartered in ARLINGTON, MA. The recorded listing date is 2017-07-20.
On this page you can find market KALA stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.